Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13405409 | 1.00 | KMT2A (0.47) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL28120493 | 0.87 | KMT2A (0.46) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL30342988 | 0.84 | KMT2A (0.43) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL30342992 | 0.84 | KMT2A (0.43) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL10564876 | 0.83 | KMT2A (0.51) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL9121966 | 0.83 | KMT2A (0.51) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL3080042 | 0.83 | KMT2A (0.51) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL12744032 | 0.83 | TSHR (0.56) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL12552579 | 0.82 | CA1 (0.43) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL14587572 | 0.82 | TBXAS1 (0.49) | KMT2ACA1CA2LTA4HEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021209427-A1 | SPIROCYCLIC NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF HEPATITIS E | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-21 | — | — | WO | disclosed |